Please provide your email address to receive an email when new articles are posted on . BOSTON — Stem cell therapies for retinal diseases come with advantages and disadvantages, according to a speaker ...
Rezolute, Inc. announced that enrollment for its Phase 3 sunRIZE study on congenital hyperinsulinism (HI) is on track to be completed by May 2025, with topline data expected in December 2025. The U.S.
PHILADELPHIA, PA — Passage Bio, Inc. (NASDAQ: PASG) has announced encouraging updates from the ongoing Phase 1/2 upliFT-D clinical trial for PBFT02, a one-time gene therapy for frontotemporal dementia ...
Not only do many people make therapy a years-long process, but they may not be getting its full benefits. Here's how to be a good consumer.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results